Printer Friendly

TELOR REPORTS DEVELOPMENT DECISIONS FOR ITS ANTI-GLAUCOMA PROGRAM

 WOBURN, Mass., Jan. 4 /PRNewswire/ -- Telor Ophthalmic Pharmaceuticals, Inc. (NASDAQ-NMS: TELR) today announced its decision on which of the previously announced alternatives would lead the company's anti-glaucoma program for TEKRON (TM). Based on encouraging preclinical data, the company currently intends to proceed with the development of both an eyedrop formulation of ethacrynic acid and a class of molecules that exhibits pharmacological activity similar to ethacrynic acid as potential new treatments for glaucoma and ocular hypertension.
 "The well-established nature and breadth of our anti-glaucoma program enabled rapid evaluation of both product options," commented Stephen J. Riggi, Ph.D., President and CEO of Telor. "In addition, the preclinical studies continue to support our belief that ethacrynic acid and certain related molecules might provide a new generation of glaucoma therapy based on a novel mechanism of action that reduces pressure by increasing fluid outflow from the eye."
 Telor has developed an eyedrop formulation of TEKRON using new excipients with the active ingredient ethacrynic acid. In a laucomatous monkey model, the new formulation reduced elevated intraocular pressure by up to 10 mm Hg. This decrease in pressure is similar to that produced by the original ointment formulation of TEKRON. Further studies in animal models suggested the absence of initial eye irritation with this eyedrop formulation.
 The company has also identified a class of molecules similar to ethacrynic acid. In a glaucomatous monkey model, treatment reduced elevated intraocular pressure by up to 10 mm Hg when applied twice daily for five days. No ocular irritation was observed in animal studies.
 "In view of the positive preclinical data, we have decided to proceed with development of both options, an eyedrop formulation of ethacrynic acid and a class of molecules similar to ethacrynic acid," said Dr. Riggi.
 In glaucoma patients, intraocular pressure increases when the fluid within the eye cannot exit normally through the outflow channels, a matrix of tissue known as the trabecular meshwork. The leading pharmaceutical treatments on the market fail to remedy this underlying condition; they suppress fluid inflow, rather than facilitating outflow. Glaucoma, an age-related disease, is the leading cause of preventable blindness in the U.S. Currently, 1.5 million people in the U.S. are under treatment for glaucoma or ocular hypertension. The current market for drugs to lower elevated intraocular pressure is approximately $0.8 billion annually.
 Telor is an ophthalmic pharmaceutical company dedicated to the development and marketing of innovative prescription pharmaceuticals for use in the treatment of age-related eye diseases and in ophthalmic surgery. The company's goal is to introduce into the worldwide ophthalmic pharmaceuticals market a broad portfolio of patent-protected products that are based on novel mechanisms of action and that offer significant improvements over existing therapies.
 The company's lead product in clinical development is XARANO (TM), a potential product currently in multicenter Phase III studies, for use during cataract surgery to prevent or reduce transient post-operative increases in intraocular pressure. In addition, a Phase I/II clinical study has recently been completed and data are being currently analyzed to assess the feasibility of a pharmaceutical approach for the treatment of presbyopia, an age-related impairment of the ability of the eye to focus on near objects. Presbyopia is currently remedied only by reading glasses or bifocals. Telor has its headquarters in Woburn, Mass.
 -0- 1/4/94
 /CONTACT: Stephen J. Riggi, Ph.D., President and Chief Executive Officer of Telor Ophthalmic Pharmaceuticals, 617- 937-0393; or Lynne H. Brum, Vice President of Feinstein Partners, 617- 577-8110; for Telor Ophthalmic Pharmaceuticals/
 (TELR)


CO: Telor Ophthalmic Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU:

JL -- NE005 -- 8757 01/04/94 08:35 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 4, 1994
Words:602
Previous Article:A.M. BEST ASSIGNS INITIAL LETTER RATINGS TO THE INTEGRITY COMPANIES
Next Article:ATL PLANS PMA FILING AND ECONOMIC OUTCOMES STUDY BASED ON BREAST ULTRASOUND CLINICAL TRIAL
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters